louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04232436: Planned Vaginal Delivery vs Planned Cesarean Delivery in Preterm Twins
Official title: Planned Vaginal Delivery vs Planned Cesarean Delivery in Preterm Twins
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Twin Pregnancy
Keywords: Mode of delivery
Prematurity
Survival at discharge
Survival without severe morbidity
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-01-18
Enrollment: 204
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Twins born at Montpellier University Hospital between 24SA and 32SA+6

Brief summary: The incidence of twin pregnancies has increased and currently accounts for 1.8% of all deliveries. 47.5% of twins are born prematurely (vs. 6% for singletons) of which 9.9% before 32SA. Caesarean section rates are also higher than for singletons (53.7% vs 19.2%) and 31.8% of caesarean sections are performed before delivery.

The optimal mode of delivery for preterm twins remains controversial. The latest recommendations for clinical practice emphasize that it is not appropriate to recommend one mode of delivery rather than another in the case of twin pregnancies at any term.

In view of all these elements, we wished to carry out a retrospective study at the Montpellier University Hospital in order to compare the neonatal outcome of preterms twins according to their mode of delivery : planned vaginal delivery versus planned cesarean delivery.


Eligibility criteria: Inclusion criteria:

* twins born at Montpellier University Hospital
* between 24SA and 32SA+6
* January 2010 to July 2019
* The mothers must have gone into labour spontaneously or after preterm rupture of membranes
* first twin in cephalic presentation

Exclusion criteria:

* twin to twin transfusion syndrome
* monoamniotic pregnancies
* cause of delivery other than preterm labor or preterm rupture of membranes
* lethal malformation
* first twin in breech or transverse presentation

Primary outcomes:
measure: survival at discharge and survival
timeFrame: during neonatal hospitalization
Secondary outcomes:
measure: survival at 2 years of corrected
timeFrame: during the first two years corrected age
measure: age without neurosensory impairment
timeFrame: during the first two years corrected age
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Florent FUCHS, PU-PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06045936: A Study of Contralateral Limb Block
Official title: Sciatic Block in Contralateral Limb for Treatment of Refractory Phantom and Residual Limb Pain; a Double-Blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Limb Pain, Phantom
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-09-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research is being done to determine if an anesthetic like Lidocaine, may be effective when injected around the sciatic nerve of the intact limb in patients with limb loss pain on the contralateral side.


Eligibility criteria: Inclusion Criteria:

* Lower extremity amputation performed more than 12 months before study enrollment
* PLP/RLP in affected amputated limb \> 4 on NRS26
* Pain duration of more than 6 months despite a trial of conservative therapies for at least 2 months, including oral medications, topical medicines, physical therapy, and physical modalities (i.e., heat, cold, transcutaneous electrical nerve stimulation, phonophoresis)
* Willingness to undergo image guided diagnostic nerve block

Exclusion Criteria:

* Refusal / inability to participate or provide consent
* Contraindications to diagnostic nerve block
* Non-neurogenic source of PLP/RLP
* Current opioid use \> 50 morphine milligram equivalents per day
* Any interventional pain treatment in the residual limb within the last 30 days
* Severe uncontrolled medical condition (i.e., hypertensive crisis, decompensated hypothyroidism)
* Use of investigational pain drug within past 30 days or other concurrent clinical trial enrollment

Primary outcomes:
measure: Change in pain
timeFrame: Baseline, 60 minutes post injection
measure: Change in Functional Improvement
timeFrame: Baseline, 5 days post-injection
Secondary outcomes:
measure: Change in disability
timeFrame: Baseline, 5 days post-injection
measure: Change in Pressure-Pain Algometry
timeFrame: Baseline, 5 days post-injection
measure: Step Count
timeFrame: 5 days post-injection
Other outcomes:
Locations:
city: Mankato
country: United States
facility: Mayo Clinic Health System - Mankato
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Cole Cheney, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00349336: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Official title: A Randomized, Open Label Trial to Assess the Steady State Pharmacokinetics of Avastin Given With Either XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Colorectal Cancer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2006-07-07
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil). Patients randomized to the XELOX arm will receive Avastin (7.5mg/kg iv) on Day 1 of each 3 week cycle; patients randomized to the FOLFOX-4 arm will receive Avastin (5mg/kg iv) on Day 1 of each 2 week cycle. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* adult patients, \>=18 years of age;
* adenocarcinoma of the colon or rectum, with metastatic or locally advanced disease;
* \>=1 target lesion.

Exclusion Criteria:

* patients who have previously received systemic treatment for advanced or metastatic disease;
* patients who have received adjuvant treatment for non-metastatic disease in past 3 months;
* previous therapy with oxaliplatin or Avastin.

Primary outcomes:
measure: Weekly Steady-state Exposure of Bevacizumab
timeFrame: Up to 48 weeks
Secondary outcomes:
measure: Time Zero to Last Measurable Plasma Concentration of Bevacizumab
timeFrame: Up to 48 weeks
measure: Steady-state Exposure of Bevacizumab From Time Zero to Tau
timeFrame: Up to 48 weeks
measure: Maximum Serum Concentration of Bevacizumab at Steady State
timeFrame: Up to 48 weeks
measure: Minimum Serum Concentration of Bevacizumab at Steady State
timeFrame: Up to 48 weeks
measure: Serum Clearance of Bevacizumab
timeFrame: Up to 48 weeks
measure: Time of Maximum Serum Concentration of Bevacizumab
timeFrame: Up to 48 weeks
measure: Volume of Distribution of Bevacizumab at Steady State
timeFrame: Up to 48 weeks
measure: Terminal Half-life of Bevacizumab
timeFrame: Up to 48 weeks
Other outcomes:
Locations:
city: Box Hill
country: Australia
city: Fitzroy
country: Australia
city: Sydney
country: Australia
city: Brampton
country: Canada
state: Ontario
city: Hamilton
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
city: Christchurch
country: New Zealand
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT04400136: PPI Therapy Impact on GERD After Sleeve Gastrectomy
Official title: Impact of Treatment With Protonic Pump Inhibitors After Laparoscopic Sleeve Gastrectomy on Gastro-esophageal Reflux Disease Symptoms: Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Gastro Esophageal Reflux
Barrett Esophagus
Bariatric Surgery Candidate
Keywords: reflux, PPI, sleeve gastrectomy
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2020-05-22
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The trial would to try to establish:

* The best post-operative PPI prescription protocol after Sleeve Gastrectomy
* The impact of PPI therapy on postoperative peptic diseases (erosive gastropathies, ulcers, duodenitis, esophagitis and/or Barrett)
* The impact of PPI therapy on post-operative GERD symptoms (assessed with the use of two standard tests: MRGE-HRQL and GERDQ

Detailed description: 45 patients candidate to primary SG and randomized in 3 study groups (15 per group) GROUP A: no treatment (control group)

GROUP B (standard dose-long term): Lansoprazole buccal tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months

GROUP C (standard dose-short term): Lansoprazole buccal tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months

Eligibility criteria: Inclusion Criteria:

* Patients candidates for primary SG
* Patients adhering to the follow-up protocol
* Age between 18 and 65 years
* No BMI limits

Exclusion Criteria:

* Gastric and/or esophageal diseases (routine preoperative endoscopy)
* Patients candidate for revisional bariatric surgery
* Chronic preoperative PPI therapy
* Using of PPI treatment for postoperative complications
* Conversion to open surgery
* Patients allergic to PPI
* Patients undergoing concomitant surgery
* Patients with hiatal hernia undergoing concomitant cruroplasty

Primary outcomes:
measure: Percentage of post-operative GERD based on the trial protocol. Clinical evaluation
timeFrame: 12 months
Secondary outcomes:
measure: evaluate in each group of the study (arm type) the endoscopic finding of peptic lesions of the esophagus-gastro-duodenal mucosa at 24 months of follow-up
timeFrame: 24 months
Other outcomes:
Locations:
city: Latina
country: Italy
facility: University of Rome "la sapienza"
Study officials:
References:
Clinical trial NCT04030936: Knowledge Regarding Diagnosis of MIH Among Dental Interns in Faculty of Dentistry Cairo University
Official title: Knowledge Regarding Diagnosis of Molar Incisor Hypomineralization Among Dental Interns in Faculty of Dentistry Cairo University
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Molar Incisor Hypomineralization
Keywords: MIH, knowledge , Molar Incisor Hypomineralization
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-07-24
Enrollment: 190
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: dental interns in faculty of dentistry Cairo university

Brief summary: assessment of knowledge of dental interns regarding diagnosis of MIH among Group of interns in faculty of dentistry Cairo university

Detailed description: The study will be done in faculty of dentistry Cairo university in form of survey with data being gathered via a questionnaire. The survey was conducted among the dental interns

Eligibility criteria: Inclusion Criteria:

* any nationality both gender

Exclusion Criteria:

* interns who refuse to participate

Primary outcomes:
measure: knowledge regarding diagnosis of MIH
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03851536: Ultrasound Guidance for Embryo Transfer
Official title: Transvaginal Versus Transabdominal Ultrasound Guided Embryo Transfer. Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: Embryo Transfer
ICSI
Transvaginal Ultrasound
Lead sponsor: Menoufia University
Sponsor class: OTHER
Collaborators: name: Alexandria University
First posted: 2019-02-22
Enrollment: 178
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized controlled study comparing the TVUS versus TAUS guidance during the procedure of embryo transfer.

Detailed description: The aim of this study was to Compare between transvaginal and transabdominal ultrasound guided embryo transfer as regarding clinical pregnancy rate, patient comfort, time required for embryo transfer and endometrial visualization at time of embryo transfer.

Eligibility criteria: Inclusion Criteria:

All patients undergoing autologous ICSI and frozen embryo transfer (FET) cycles.

Exclusion Criteria:

1. Cases of sever ovarian hyperstimulation requiring embryo cryopreservation
2. Gestational surrogate cycles
3. Oocyte donation cycles
4. Very poor responders
5. Patients with inadequate visualization of the uterus by ultrasound.
6. Very difficult mock embryo transfer.

Primary outcomes:
measure: Clinical pregnancy
timeFrame: 3 weeks after Embryo transfer
Secondary outcomes:
measure: Time required for ET
timeFrame: Time from when the catheter is handed to the transferring physician to the time it is returned to the transferring embryologist.
measure: Degree of cramping and pain
timeFrame: During and immediately after ET
measure: Endometrial visualization at time of embryo transfer
timeFrame: During ET
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Menoufia University
state: Monofiya
city: Alexandria
country: Egypt
facility: Alexandria University
Study officials:
affiliation: Menoufia University
name: Mohamad S kandil, MD
role: STUDY_CHAIR
affiliation: Alexandria University
name: Sherif S Gaafar, MD
role: STUDY_DIRECTOR
affiliation: Menoufia University
name: Haitham A Hamza, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05069636: Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy
Official title: Lymphatic Osteopathic Manipulative Medicine to Enhance COVID-19 Vaccination Efficacy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: COVID-19
Keywords: COVID-19
Osteopathic Manipulative Medicine
Antibody
Lead sponsor: Rowan University
Sponsor class: OTHER
First posted: 2021-10-06
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this project is to study the impact of Osteopathic Manipulative Medicine (OMM) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels in patients who receive the mRNA-1273 (Moderna) COVID-19 vaccine and to consider if these OMM strategies allow a stronger more robust immune response.


Eligibility criteria: Inclusion Criteria:

* Inclusion criteria will include age greater than 18 years old and having safely received the COVID-19 vaccine.

Exclusion Criteria:

* Exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. Lymphatic OMM is safe during pregnancy and this does not need to be an exclusion criteria.

Primary outcomes:
measure: severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels
timeFrame: The day of first vaccine dose (baseline), the day of second vaccine dose (at about 4-weeks post first vaccine dose), and 2-weeks post second vaccine dose (at about 6-weeks post first vaccine dose
Secondary outcomes:
Other outcomes:
Locations:
city: Stratford
country: United States
facility: Rowan University School of Osteopathic Medicine
state: New Jersey
Study officials:
References:
Clinical trial NCT05280236: Comparison of Quality of Recovery Between Remimazolam and Propofol Anesthesia in Patients Undergoing Arthroscopic Meniscectomy
Official title: Comparison of Quality of Recovery Between Remimazolam and Propofol Anesthesia in Patients Undergoing Arthroscopic Meniscectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adult Patients 19 or Older Scheduled for Elective Arthroscopic Meniscectomy
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2022-03-15
Enrollment: 80
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to compare quality of recovery after surgery and anesthesia between patients undergoing arthroscopic meniscectomy under general anesthesia with either propofol or remimazolam based total intravenous anesthesia. This study is a randomized trial with a 50% probability of being assigned to either group. Randomization will be done by an anesthesiologist not involved in anesthesia or postoperative outcome assessment. Patients and the investigator in charge of postoperative outcomes assessment will be blinded to group allocation.


Eligibility criteria: Inclusion Criteria:

* Adult patients 19 or older, ASA class I\~III,
* scheduled for arthroscopic meniscectomy under general anesthesia and eligible for LMA use.

Exclusion Criteria:

* Patient refusal,
* patients unable to read consent form, active URI or uncontrolled asthma,
* pneumonia,
* history of allergies to propofol or benzodiazepines,
* decreased liver or kidney function, heart failure of ejection fraction\<55%,
* pregnant or breastfeeding patients,
* history of substance abuse/addiction

Primary outcomes:
measure: Quality of Recovery (QoR)-40 questionnaire
timeFrame: Postoperative 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Health System, Severance Hospital
Study officials:
References:
Clinical trial NCT01999036: Save Hearts in Arizona Registry and Education (SHARE) Project
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Out-of-hospital Cardiac Arrest
Keywords: cardiac arrest, CPR, resuscitation
Lead sponsor: University of Arizona
Sponsor class: OTHER
Collaborators: name: Arizona Department of Health Services
First posted: 2013-12-03
Enrollment: 20000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Out-of-hospital cardiac arrest patients on which resuscitation was attempted by Emergency Medical Services in the state of Arizona

Brief summary: Evaluation of the impact of bystander CPR, prehospital resuscitation protocols, and hospital post-resuscitation protocols for out-of-hospital cardiac arrest patients in the state of Arizona.


Eligibility criteria: Inclusion Criteria:

* Out of Hospital Cardiac Arrest (loss of spontaneous circulation and EMS attempted resuscitation)

Exclusion Criteria:

* Do Not Resuscitate

Primary outcomes:
measure: Survival to hospital discharge
timeFrame: Upon hospital discharge and annually up to 5 years
Secondary outcomes:
measure: Emergency Medical Services Cardiopulmonary Resuscitation (CPR) quality
timeFrame: Prehospital resuscitation
Other outcomes:
measure: Frequency and Quality of Telephone Cardiopulmonary Resuscitation (CPR)
timeFrame: During 9-1-1 call
measure: Proportion of out-of-hospital cardiac arrest patients receiving bystander Cardiopulmonary Resuscitation (CPR)
timeFrame: Time of cardiac arrest to EMS arrival
measure: Proportion of out-of-hospital cardiac arrest patients transported to a recognized Cardiac Receiving Center
timeFrame: Emergency Medical Services (EMS) patient encounter
measure: Proportion of out-of-hospital cardiac arrest patients receiving Guideline post-arrest care
timeFrame: Hospital admission to hospital discharge/death
measure: Post cardiac arrest care process
timeFrame: Hospital admission to hospital discharge/death
Locations:
city: Multiple Locations
country: United States
state: Arizona
Study officials:
References:
citation: Irisawa T, Vadeboncoeur TF, Karamooz M, Mullins M, Chikani V, Spaite DW, Bobrow BJ. Duration of Coma in Out-of-Hospital Cardiac Arrest Survivors Treated With Targeted Temperature Management. Ann Emerg Med. 2017 Jan;69(1):36-43. doi: 10.1016/j.annemergmed.2016.04.021. Epub 2016 May 27.
Clinical trial NCT03006536: Low-Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: A Randomized, Controlled, Double Blind Trial
Official title: Low-Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: A Randomized, Controlled, Double Blind Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Erectile Dysfunction
Lead sponsor: Zealand University Hospital
Sponsor class: OTHER
First posted: 2016-12-30
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proposed mechanism of action for LI-ESWT in ED is that it improves endothelial function and triggers angiogenesis through induction of local growth factors and endothelial nitric oxide synthase. The literature generally confirms that LI-ESWT is safe and cohort studies investigating the clinical effects have been encouraging. Meanwhile, randomized trials have shown contradictory results. Thus, a randomized trial in 67 PDE5-I responders showed statistically greater improvements in the Erectile Function Domain of the International Index of Erectile Function (IIEF) with active LI-ESWT treatment compared to a sham treatment (p=0.032).


Eligibility criteria: Inclusion Criteria:

* Age 18-70 years
* A history of erectile dysfunction for \>6 months
* IIEF-ED score \< 25
* In a stable heterosexual relationship for at least 6 months
* Willingness to attempt sexual intercourse at least twice per week during the study and follow-up

Exclusion Criteria:

* Psychogenic ED as assessed by a standardized interview (attachment 2)
* Known psychiatric illness
* Neurological disease (including Parkinson's disease, Multiple sclerosis, spinal cord injury, and a history of stroke)
* Traumatic nerve injury
* Previous pelvic surgery or radiation
* Heart disease in the form of unstable angina, NYHA class \>II heart failure, uncontrolled arrhythmia, or significantly symptomatic and/or severe valvular disease
* Endocrine disease including hypogonadism (total testosterone \<12 nmol/l)
* Insulin dependent or uncontrolled diabetes mellitus
* Dependence on erectogenic aids other than PDE5-Inhibitors
* Use of medications which have been shown to interfere with erections
* Use of anticoagulant medications other than low dose aspirin
* Active cancer
* A diagnoses of Peyronie's disease and/or prior occurrence of priapism
* Alcohol abuse (more than 21 containers of alcohol per week)

Primary outcomes:
measure: International Index of Erectile Function (IIEF)
timeFrame: 1 months
Secondary outcomes:
Other outcomes:
Locations:
city: Roskilde
country: Denmark
facility: Zealand University Hospital
Study officials:
References: